Explanipedia

Stereotactic Radiotherapy to the Prostate and Pelvic Lymph Nodes for High-Risk and Very High-Risk Prostate Cancer in a Setting with a Hydrogel Spacer: A Toxicity Report Open

Elisha Fredman, Roi Tschernichovsky, Danielle Shemesh, Miriam Weinstock-Sabbah, Ruth Dadush Azuz , et al. · 2025

Background/Objectives: Stereotactic radiotherapy (SABR) is a recognized standard treatment modality for localized prostate cancer, though data is limited regarding the risk of increased toxicity when including the elective nodes (ENI) for …

BRAF inhibitor or BRAF/MEK inhibitor treatment for patients with metastatic BRAF V600E mutated differentiated thyroid cancer Open

Inbar Finkel, Yasmin Korzets, Assaf Moore, Tara Coreanu, Aron Popovtzer , et al. · 2025

Dabrafenib in combination with trametinib was well tolerated and resulted in substantial clinical benefit, with notable PFS and sustained OS, even as a second-line treatment, in patients diagnosed with metastatic, progressive BRAF V600E-mu…

The role of a radiopaque peri-rectal hydrogel spacer in aiding accurate daily image-guidance for prostate stereotactic radiotherapy Open

Oded Icht, Shir Schlosser, Miriam Weinstock-Sabbah, Mor Rephael, Dimitri Bragilovski , et al. · 2024

Introduction Precise patient positioning with image guidance (IGRT) is essential for safe prostate radiotherapy. We present the first report of utilizing a CT-visible hydrogel spacer, used to decrease rectal radiation dose, as a surrogate …

SABR-Dual: a phase II/III trial of two-fraction versus five-fraction stereotactic radiotherapy for localized low- and favorable intermediate-risk prostate cancer Open

Elisha Fredman, Oded Icht, Assaf Moore, Dimitri Bragilovski, Jonathan Kindler , et al. · 2024

Background Dose-escalated radiotherapy is known to improve progression free survival in patients with localized prostate cancer, and recent advances have led to the standardization of ultrahypofractionated stereotactic ablative radiotherap…

SABR-Dual: A phase II/III trial of two-fraction versus five-fraction stereotactic radiotherapy for localized low- and favorable intermediate-risk prostate cancer Open

Elisha Fredman, Oded Icht, Assaf Moore, Dimitri Bragilovski, Yoni Kindler , et al. · 2023

Background: Dose-escalated radiotherapy is known to improve progression free survival in patients with localized prostate cancer, and recent advances have led to the standardization of ultrahypofractionated stereotactic ablative radiothera…

Same-day versus delayed simulation imaging after placement of a perirectal hydrogel spacer for prostate radiotherapy Open

Elisha Fredman, Miriam Weinstock-Sabbah, Oded Icht, Assaf Moore, Tzippora Shochet , et al. · 2023

Introduction Placement of a perirectal hydrogel spacer has been demonstrated to reduce the risk of rectal toxicity from prostate radiation. Practices vary regarding the timing of CT simulation after hydrogel placement, and the ideal schedu…

Hypofractionated Radiation Therapy (Hypo-RT) for the Treatment of Localized Bladder Cancer Open

Assaf Moore, Stephanie Lobaugh, Zhigang Zhang, Jonathan E. Rosenberg, Gopa Iyer , et al. · 2023

BACKGROUND: Various radiotherapeutic regimens are used in the treatment of bladder cancer. OBJECTIVE: We aimed to evaluate early toxicity and outcomes associated with hypofractionated radiation therapy (Hypo-RT), 55Gy in 20 fractions. MATE…

Health Disparities in Prostate Cancer and Approaches to Advance Equitable Care Open

Cyrus Washington, Daniel A. Goldstein, Assaf Moore, Ulysses Gardner, Curtiland Deville · 2022

The American Cancer Society estimates approximately 268,490 new cases of prostate cancer and approximately 34,500 deaths caused by prostate cancer in the United States for 2022. Globally, a total of 1,414,259 new cases of prostate cancer a…

Local Failure after Prostate SBRT Predominantly Occurs in the PI-RADS 4 or 5 Dominant Intraprostatic Lesion Open

Daniel Gorovets, Andreas G. Wibmer, Assaf Moore, Stephanie Lobaugh, Zhigang Zhang , et al. · 2022

The Cost of Enfortumab Vedotin Wastage Due to Vial Size—A Real-World Analysis Open

Michal Sarfaty, Assaf Moore, Ashley Marie Regazzi, Aaron Philip Mitchell, Jonathan E. Rosenberg · 2021

Enfortumab Vedotin (EV) is FDA-approved for advanced urothelial cancer in patients previously treated with platinum-based chemotherapy and a checkpoint inhibitor. We conducted a real-world study to determine the extent of EV wastage in a s…

Prognostic impact of HER2-low expression in hormone receptor positive early breast cancer Open

Raz Mutai, Tamar Barkan, Assaf Moore, Michal Sarfaty, Tzippy Shochat , et al. · 2021

The impact of endogenous estrogen exposures on the characteristics and outcomes of estrogen receptor positive, early breast cancer Open

Yasmin Korzets, Orly Yariv, Raz Mutai, Assaf Moore, Tzippy Shochat , et al. · 2021

Use of Continuous Positive Airway Pressure (CPAP) to Limit Diaphragm Motion—A Novel Approach for Definitive Radiation Therapy for Inoperable Pleural Mesothelioma: A Pilot Study Open

Assaf Moore, Marc Jose Jonathan Kindler, Aaron M. Allen · 2021

Malignant pleural mesothelioma (MPM) is a deadly disease and radiotherapy (RT) plays an important role in its management. Recent developments in technique have made it is possible to deliver RT to MPM in the intact lung. However, it is imp…

Next-generation sequencing in thyroid cancers: do targetable alterations lead to a therapeutic advantage? Open

Assaf Moore, Yael Bar, Corinne Maurice‐Dror, Inbar Finkel, Hadar Goldvaser , et al. · 2021

Radioiodine-refractory thyroid cancers (IRTCs) are uncommon and have a poor prognosis. Treatment options for radioiodine-refractory and anaplastic tumors (ATCs) are limited. Although the genomic landscape of thyroid cancer has been studied…

Locoregional therapy in de novo metastatic breast cancer: Systemic review and meta-analysis Open

Daniel Reinhorn, Raz Mutai, Rinat Yerushalmi, Assaf Moore, Eitan Amir , et al. · 2021

The Impact of Endogenous Estrogen Exposures on the Characteristics and Outcomes of Estrogen Receptor Positive, Early-stage Breast Cancer Open

Yasmin Korzets, Orly Yariv, Raz Mutai, Assaf Moore, Tzippy Shochat , et al. · 2021

Background : Menstrual and parity history might impact the risk for breast cancer. Data on the impact of these factors on other tumor characteristics are limited. Methods : A single center retrospective cohort study comprising all women wi…

BAP1-Altered Malignant Pleural Mesothelioma: Outcomes With Chemotherapy, Immune Check-Point Inhibitors and Poly(ADP-Ribose) Polymerase Inhibitors Open

Elizabeth Dudnik, Jair Bar, Assaf Moore, Teodor Gottfried, Mor Moskovitz , et al. · 2021

Objectives Little is known regarding the outcomes of systemic treatments in BAP1-altered malignant pleural mesothelioma (MPM). Materials and Methods Forty five patients with MPM [group A: eight MPM patients with BAP1 inactivating mutation/…

Supplementary Material for: The Impact of Exogenous Estrogen Exposure on the Characteristics and Outcome of Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early-Stage Breast Cancer Open

Orly Yariv, Raz Mutai, Ofer Rotem, Daliah Tsoref, Yasmin Korzets , et al. · 2021

Introduction: The impact of exogenous estrogen exposure on breast cancer characteristics and outcomes is not well described. We aimed to investigate the effect of prior treatment with oral contraceptives (OCT), hormone replac…

Potential Association between Kaposi Sarcoma and Gout: An Exploratory Observational Study Open

Assaf Moore, Idit Peretz, Lilach Yosef, Daniel A. Goldstein, Hadar Goldvaser , et al. · 2020

Background. Kaposi sarcoma is a rare vascular mesenchymal neoplasm, associated with Human Herpes Virus 8 (HHV8). Gout is a condition clinically characterized by recurrent flares of arthritis and hyperuricemia. Following our clinical impres…

Volumetric modulated arc therapy (VMAT) is superior to intensity modulated radiotherapy (IMRT) for liver sparing in SBRT for hepatocellular carcinoma Open

Yulia Kundel, Yasmin Korzets, Miriam Weinstock-Sabbah, Assaf Moore, Noa Gordon , et al. · 2020

Background: The best delivery modality of stereotactic body radiotherapy (SBRT) for hepatocellular carcinoma (HCC) from a technical point of view is still a matter of debate. The purpose of this study was to compare planning parameters wit…

Alternative nivolumab duration and scheduling in advanced nonsmall cell lung cancer: A real‐world evidence Open

Elizabeth Dudnik, Mor Moskovitz, Abed Agbarya, Teodor Gottfried, Tzippy Shochat , et al. · 2020

In advanced nonsmall cell lung cancer (aNSCLC), stopping nivolumab after 12 months negatively affects outcomes. We performed a world data‐based analysis assessing the value of nivolumab continuation and optimal dosing beyond 24 months. Out…

Efficacy of immune‐checkpoint inhibitors in metastatic gastric or gastroesophageal junction adenocarcinoma by patient subgroups: A systematic review and meta‐analysis Open

Yulia Kundel, Michal Sternschuss, Assaf Moore, Gali Perl, Baruch Brenner , et al. · 2020

Background Efficacy of immune checkpoint inhibitors (ICIs) in metastatic gastric/gastroesophageal junction (GEJ) adenocarcinoma is inconsistent. Whether the efficacy of ICIs is comparable across different subgroups remains unknown. Methods…

Issue Information Open

Ehab Y. Hanna, Mariann Crapanzano, Anita Bell, Athanassios Argiris, San Antonio , et al. · 2020

US), US$4523 (Rest of World), €2925 (Europe), £2314 (UK).

The effect of radiotherapy on taste sensation in head and neck cancer patients – a prospective study Open

Michal Asif, Assaf Moore, Noam Yarom, Aron Popovtzer · 2020

The concordance of treatment decision guided by OncotypeDX and the PREDICT tool in real‐world early‐stage breast cancer Open

Daniel A. Goldstein, Chen Mayer, Tzippy Shochat, Daniel Reinhorn, Assaf Moore , et al. · 2020

Background Decision‐making regarding adjuvant chemotherapy for early‐stage breast cancer can be guided by genomic assays such as OncotypeDX. The concordance of expected clinical decisions guided by OncotypeDX and prognostication online too…

Stereotactic body radiation therapy (SBRT) for the treatment of primary lung cancer in recipients of lung transplant Open

Assaf Moore, Mordechai R. Kramer, Dror Rosengarten, Osnat Shtraichman, Alona Zer , et al. · 2020

Background Lung transplantation is a life-saving treatment for patients with end stage lung disease. There may be a higher incidence of lung cancer in lung transplant recipients, and these cancers tend to be diagnosed at a more advanced st…

Young-onset gastric cancer and Epstein–Barr Virus (EBV) – a major player in the pathogenesis? Open

Assaf Moore, Elad Hikri, Tal Goshen‐Lago, Tamar Barkan, Sara Morgenstern , et al. · 2020

A Cost-Effectiveness Analysis of Nivolumab and Ipilimumab Versus Sunitinib in First-Line Intermediate- to Poor-Risk Advanced Renal Cell Carcinoma Open

Daniel Reinhorn, Michal Sarfaty, Moshe Leshno, Assaf Moore, Victoria Neiman , et al. · 2019

Background The treatment paradigm of advanced renal cell carcinoma (RCC) has changed rapidly in recent years. In first-line treatment of intermediate- to poor-risk patients, the CheckMate 214 study demonstrated a significant survival advan…

The Financial Impact of Hypofractionated Radiation for Localized Prostate Cancer in the United States Open

Assaf Moore, Ido Stav, Robert B. Den, Noa Gordon, Michal Sarfaty , et al. · 2019

Background . Until recently, dose intensified radiotherapy was the standard radiation method for localized prostate cancer. Multiple studies have demonstrated similar efficacy and tolerability with moderate hypofractionation. In recent yea…

Early PET‐CT in patients with pathological stage III colon cancer may improve their outcome: Results from a large retrospective study Open

Assaf Moore, Olga Ulitsky, Irit Ben‐Aharon, Gali Perl, Yulia Kundel , et al. · 2018

Background Current staging of pathological stage III colon cancer (CC) is suboptimal; many patients recur despite unremarkable preoperative staging. We previously reported that early postoperative PET‐CT can alter the stage and management …

Assaf Moore YOU? Author Swipe